Sat 11/18/2017 18:05 ET
DJIA23358.24100.120.43%SOLAR24.550.140.57%GOLD1294.3916.181.25%Shanghai3136.7734.501.10%
S&P 5002578.856.710.26%BANKS26.160.020.08%OIL56.611.472.60%Nikkei22420.08417.011.86%
NASDAQ6782.7910.170.15%SEMI103.251.621.57%US/EU1.180.000.11%Futures2576.258.750.34%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (AcelRx Pharmaceuticals, Inc. - ACRX)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ACRX
  
From: singhtelecom (Rep: 956) reply to singhtelecomDate: 07/16/2017 00:27
Forum: Wall Street Pit - Msg #2682636 - List ACRX msgs Thread #673937598 (Rec: 0)
moving 20% so far could see 5 by december Re: In 2014, AcelRx Pharmaceuticals was stunned by the U.S. Food and Drug Adminis...



Reply to singhtelecom - Msg #2681585 - 07/08/2017 23:12

In 2014, AcelRx Pharmaceuticals was stunned by the U.S. Food and Drug Administration's negative decision on approval of Zalviso, a combination drug/device system that delivers sufentanil for treating acute pain. At the time, AcelRx thought it could address the FDA's concerns and resubmit Zalviso for approval by the end of the year. That didn't happen.

Instead, the company ended up having to conduct an additional clinical study. This late-stage study finally began in September 2016 and is scheduled to wrap up in July 2017. If the results from this study are positive, AcelRx hopes to resubmit Zalviso to the FDA later this year.
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser singhtelecom: Reward | Watch | IgnoreACRX: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ACRX
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.